At KACTUS, they have developed a highly-active, wild-type Cas9 nuclease based on their SAMS™ technology platform.
KACTUS: CRISPR Cas9 Protein
February 2017: The Antibody Update
Epidermal Levels of Staphylococcus Aureus Are Affected by a Peptide Produced by Other Skin Dwelling Bacteria Staphylococcus aureus is common to many of people’s ski n microbiome, and is generally harmless; however, in high population density the bacteria can lead to atopic
November 2016: The Antibody Update
China Perform First Injection of CRISPR Modified Cells into a Person Use of CRISPR-Cas9 in human cells for treatment of disease has been a controversial topic amongst scientists since the discovery of the powerful gene editing tool. In this clinical
September 2016: The Antibody Update From ProSci
ProSci’s top news picks for September 2016 include a paper on a novel monoclonal antibody against parenchymal amyloid-beta for the treatment of Alzheimer’s Dementia, a scientist using CRISPR for gene editing of embryos, and an update on the discussion of
June 2016: The Antibody Update from ProSci
This months ProSci Antibody Update’s news includes the first CRISPR/Cas9 cancer therapeutic’s entry into clinical trials, how mosquito saliva assists viruses in proliferation, and the latest update on antibody validation. First CRISPR/Cas9 Therapeutic Clinical Trials StartingProSci Blog Antibody UpdateCRISPR Cas9